Cosmetics and Beauty Products Sector Outlook — September 2026
A NeuraCap sector outlook on Cosmetics and Beauty Products as of September 2026, covering public-market valuation, precedent transactions and strategic implications for owners, management teams and boards assessing branded and adjacent beauty business models.
For information only. Not an appraisal or a fairness opinion.
What moved since: Cosmetics and Beauty Products M&A update, 14–28 September 2026
Key figures
- Premium tier valuation
- 23.2x
- EV/EBITDA (CY2027E), premium end
- Discount tier valuation
- 5.8x
- EV/EBITDA (CY2027E), discount end
- Sector median multiple
- 15.2x
- EV/EBITDA (CY2027E), rated set
- Faster-growth cohort multiple
- 15.8x
- vs 13.2x for slower-growth cohort
Read the report
1 / 21 · CONSUMER STAPLES › HOUSEHOLD AND PERSONAL PRODUCTS › COSMETICS AND BEAUTY PRODUCTS
Executive summary
Cosmetics and Beauty Products do not trade as one uniform market: branded platforms dominate the set, and adjacent models widen the valuation range. On an EV/EBITDA (CY2027E) basis, the premium end trades at 23.2x against 5.8x at the discount end, and faster-growing names carry the higher multiple. Margin alone does not explain the ranking, so business-model quality and growth durability are the questions owners and boards should resolve next.
Key findings
- Premium platforms trade at 23.2x versus 5.8x at the discount end.
- Faster-growing names carry higher forward multiples: 15.8x versus 13.2x.
- Sector median stands at 15.2x EV/EBITDA (CY2027E) across rated names.
- Margin alone does not sort valuation; growth and model type matter more.
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01
CONSUMER STAPLES › HOUSEHOLD AND PERSONAL PRODUCTS › COSMETICS AND BEAUTY PRODUCTS
Cover slide introducing the September 2026 Cosmetics and Beauty Products sector outlook.
We open with the state of play across Cosmetics and Beauty Products as of September 28, 2026, framed on an EV/EBITDA (CY2027E) basis. This sets up why branded platforms and adjacent models command different valuation positions.
Everything on this page
CONSUMER STAPLES › HOUSEHOLD AND PERSONAL PRODUCTS › COSMETICS AND BEAUTY PRODUCTS Beauty Products: The Market Prices Distinct Models This report shows where forward valuations sit and which operating questions matter most. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1
- 02CONTENTS
What This Report Covers
This slide lists the report's five sections plus the appendix.
We walk through five sections — the bottom line, the market landscape, valuation and situations, precedent transactions and strategic implications — plus a full appendix. The Bottom Line comes first so a reader who stops after section one still leaves with the complete story. So what: that structure lets us move quickly to what matters most for capital allocation decisions.
Everything on this page
CONTENTS What This Report Covers 01 The Bottom Line Beauty Valuations Separate on Growth, Profit and Operating Proof 02 The Landscape Branded Beauty Dominates the Set, While Adjacent Models Widen the Range 03 Valuation & Situations The Premium End Remains Well Clear of the Discount End 04 Precedent Transactions Disclosed Deal Values Sit Alongside a Wide EBITDA Range 05 Strategic Implications Durable Growth Requires Proof at the Consumer, Product and Channel Level 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2
- 0301 · THE BOTTOM LINE
Cosmetics and Beauty Products Split Between Branded Platforms and Adjacent Models
This slide summarizes the finding that the sector splits between branded platforms and adjacent models.
We show the full story in one page: branded platforms and adjacent business models occupy different points on the valuation curve, measured on EV/EBITDA (CY2027E) across 7 of 9 rated companies. The premium end trades well above the discount end, and faster growth tracks with higher forward multiples. So what: capital allocation and operating priorities should follow business-model economics, not a single sector average.
Everything on this page
01 · THE BOTTOM LINE Cosmetics and Beauty Products Split Between Branded Platforms and Adjacent Models The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 9 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Premium End Sits Far Above the Discount End The premium end stands at 23.2x, compared with 5.8x at the discount end. That spread makes the durability of growth, brand economics and channel position central to the valuation discussion. 2 Faster Growth Sits with the Higher Multiple Among the 3 companies above the 9% growth split, forward EV / EBITDA is 15.8x. Among the 3 companies below it, the figure is 13.2x, an observed association rather than proof that growth alone accounts for the difference. 3 Profit Is the Right Lens for This Set 7 of 9 companies have a forward EV / EBITDA estimate, and the 7 companies with a forward EV / EBITDA estimate carry meaningful reported forward EBITDA. This lens captures economics after A and P investment, trade spend and allowances. 4 Buyer Diligence Reaches Beyond Headline Growth 6 of the 9 transactions disclose EV / EBITDA, but operating fit still varies by target. Sell-in versus sell-out, franchise extension, licence terms and space productivity shape how buyers test durability. 15.2x Sector median EV/EBITDA CY2027E consensus · 7 rated of 9 companies 23.2x Premium end EV/EBITDA vs 5.8x at the discount end top quartile (n=2) against bottom quartile (n=2) on EV/EBITDA — the spread the report explains 15 Transactions with disclosed terms 33 recorded in this tier · 3 told as case studies, the full list in the appendix
- 04SECTION 02
02
Divider introducing the market map section.
This section maps branded beauty against adjacent business models that carry different economics. So what: understanding where each company sits sets up the valuation comparisons that follow.
Everything on this page
SECTION 02 02 THE LANDSCAPE Branded Beauty Dominates the Set, While Adjacent Models Widen the Range The map combines brand-led businesses with models that carry different economics. 02 of 06 Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4
- 0502 · MARKET MAP
Mass Personal Care Brands Set the Centre of Gravity
This slide groups the 9 approved companies by business segment with median EV/EBITDA (CY2027E) per group.
We group all 9 approved companies by business segment and show each group's median EV/EBITDA (CY2027E) as of September 28, 2026. Mass personal care brands anchor the centre of gravity for the set. So what: segment placement is the first filter for understanding why multiples diverge across the peer group.
Everything on this page
02 · MARKET MAP Mass Personal Care Brands Set the Centre of Gravity 9 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 MASS PERSONAL CARE BRANDS 7 cos median 15.2x The Estée Lauder (EL) e.l.f. Beauty (ELF) Coty (COTY) Inter Parfums (IPAR) Oddity Tech (ODD) Yatsen Holding (YSG) Solesence, Inc. (SLSN) This group represents 78% of the set and concentrates the brand, innovation and retailer questions that define beauty economics. ADJACENT MODELS 2 cos median 14.5x LandBridge Company (LB) Betterware de (BWMX) This 22% of the set widens the lens beyond branded beauty and carries materially different operating exposures.
- 0602 · LANDSCAPE
Branded Beauty Sets the Benchmark, but Adjacent Models Remain Close
This slide compares segment medians to show branded beauty against adjacent models.
We line up segment-level EV/EBITDA (CY2027E) medians on rated names to show branded beauty setting the benchmark while adjacent models stay close behind. Full company-level detail sits in the appendix for any name a client wants to trace. So what: the gap between segments is narrow enough that business-model quality, not category label, decides where a name sits.
Everything on this page
02 · LANDSCAPE Branded Beauty Sets the Benchmark, but Adjacent Models Remain Close Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Mass personal care brands 7 78% 15.2x The Estée Lauder Companies Inc. (EL) · e.l.f. Beauty, Inc. (ELF) · +5 more Brands dominate the set. The group sits at 15.2x and spans prestige, mass and masstige exposures. Value depends on repeat purchase, newness, hero franchise depth and defensible retailer position. Adjacent models 2 22% 14.5x LandBridge Company LLC (LB) · Betterware de Mexico, S.A.P.I. de C.V. (BWMX) Adjacencies widen the lens. The group sits at 14.5x and includes models whose economics are less directly tied to a conventional beauty brand portfolio. Their inclusion shows why business model matters alongside the headline sector label.
- 07SECTION 03
03
Divider introducing the valuation section.
This section examines how forward EV/EBITDA spreads from the premium end to the discount end and what sits behind that gap. So what: forward multiples already price in growth expectations, raising the bar for durability.
Everything on this page
SECTION 03 03 VALUATION & SITUATIONS The Premium End Remains Well Clear of the Discount End Forward EV / EBITDA already credits forecast growth, raising the bar for durability. 03 of 06 Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7
- 0803 · PUBLIC MARKET VALUATION
The Premium End Holds a Clear Lead on Forward Valuation
This slide ranks all 7 rated companies by EV/EBITDA (CY2027E) against a 15.2x sector median.
We sort all 7 rated companies by EV/EBITDA (CY2027E), with the sector median at 15.2x. The premium end holds a clear lead, at 23.2x, over the discount end at 5.8x. So what: that spread is the clearest single signal of where the market rewards durability and where it does not.
Everything on this page
03 · PUBLIC MARKET VALUATION The Premium End Holds a Clear Lead on Forward Valuation EV / EBITDA (CY2027E) · all 7 rated companies, sorted descending · sector median 15.2x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 9 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 23.2x CORE · median 15.2x DISCOUNT · median 5.8x Sector median 15.2x WHAT SEPARATES THE TWO ENDS The endpoints stay far apart. The premium end sits at 23.2x, while the discount end sits at 5.8x. The gap supports a company-specific review rather than a single sector-wide valuation assumption. Forecasts are already credited. Because the lens is forward EV / EBITDA, the ranking already reflects forecast growth and profit. A premium that remains under this lens sits alongside expectations for durability beyond the forecast period. Operating proof still matters. For beauty brands, the relevant proof includes consumer offtake, repeat purchase, space productivity, franchise extension and disciplined A and P investment.
- 0903 · VALUATION DRIVERS
Faster-Growing Names Carry the Higher Forward Multiple
This slide splits rated names into growth and margin cohorts and compares their median EV/EBITDA (CY2027E).
We split the rated names into faster- and slower-growth cohorts and into higher- and lower-margin cohorts, each cut at its own covered median. The companies above the growth split trade at 15.8x versus 13.2x for those below it. So what: growth tracks with a higher forward multiple in this set, though we read that as an association, not a proven cause.
Everything on this page
03 · VALUATION DRIVERS Faster-Growing Names Carry the Higher Forward Multiple Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=3; slower n=3; higher-margin n=3; lower-margin n=3). Driver readings are NeuraCap views on the supplied data — association, not causation. Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/EBITDA, median per cohort · growth split at 9% · EBITDA-margin split at 18% The Growth Split Points to a Valuation Difference Among the 3 companies above 9% growth, forward EV / EBITDA is 15.8x. Among the 3 companies below 9% growth, it is 13.2x. Margin Alone Does Not Sort the Ranking Oddity Tech Ltd. (ODD) sits at 20.9x with an 8% margin, while Betterware de Mexico, S.A.P.I. de C.V. (BWMX) sits at 3.6x with a 20% margin. The contrast indicates that the market is weighing more than current profitability. Beauty Growth Needs Product and Channel Proof The durability test is whether growth reflects consumer offtake, productive doors and repeatable franchise extension rather than shipment timing, promotion or a single hero SKU.
- 1003 · SITUATION MAP
Margin and Multiple Create Four Different Operating Agendas
This slide plots companies on EV/EBITDA against EBITDA margin relative to the sector's medians.
We cut the rated set on EV/EBITDA versus the 15.2x sector median and on EBITDA margin versus the 18% covered median, producing four distinct operating positions. These are observations on where each name sits, not recommendations. So what: margin and multiple together frame four different operating agendas, and each calls for a different response.
Everything on this page
03 · SITUATION MAP Margin and Multiple Create Four Different Operating Agendas Cut on EV / EBITDA vs the sector median (15.2x) (rows) and EBITDA margin vs the covered median (18%) (columns) · 1 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Premium with Profit Above-median multiple · above-median EBITDA margin 1 names e.l.f. Beauty, Inc. (ELF) The one company in this position is e.l.f. Beauty, Inc. (ELF). Its standing combines an above-middle multiple with an above-middle EBITDA margin, placing durability and reinvestment discipline at the centre of the agenda. Premium Before Margin Above-median multiple · below-median EBITDA margin 2 names Inter Parfums, Inc. (IPAR) · Oddity Tech Ltd. (ODD) The 2 companies in this position are Inter Parfums, Inc. (IPAR) and Oddity Tech Ltd. (ODD). Their above-middle multiples sit beside below-middle EBITDA margins, making future margin conversion and revenue quality important tests. Profit Before Premium Below-median multiple · above-median EBITDA margin 2 names The Estée Lauder Companies Inc. (EL) · Betterware de Mexico, S.A.P.I. de C.V. (BWMX) The 2 companies in this position are The Estée Lauder Companies Inc. (EL) and Betterware de Mexico, S.A.P.I. de C.V. (BWMX). Their above-middle EBITDA margins have not been matched by above-middle multiples, pointing attention toward growth durability, mix and channel confidence. Rebuild Both Below-median multiple · below-median EBITDA margin 1 names Coty Inc. (COTY) The one company in this position is Coty Inc. (COTY). Both measures sit below the middle of the set, so the operating debate spans growth, margin structure and portfolio focus.
- 1103 · THE AGENDA
The Right Operating Move Depends on the Source and Quality of Growth
This slide frames the operating questions an owner or acquirer should resolve based on the source and quality of growth.
We lay out the questions an owner or acquirer should resolve depending on where growth comes from and how durable it looks. This is a directional view grounded in the cohort data shown earlier, offered as observation rather than advice. So what: the right operating move depends on distinguishing durable consumer demand from shipment-driven growth.
Everything on this page
03 · THE AGENDA The Right Operating Move Depends on the Source and Quality of Growth NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Turn Hero Products into Franchises Extend proven hero SKUs into repeatable franchises without diluting the core proposition or adding unproductive shade and SKU tail. What changes the answer: The answer changes when repeat purchase and franchise extensions begin to contribute more consistently than launch-driven demand. Choose Velocity Before Door Count Balance distribution expansion against sales per door, retailer concentration and planogram-reset exposure. What changes the answer: The answer changes when new doors add sustained consumer offtake without weakening space productivity. Protect Productive Brand Investment Direct A and P investment, trade spend and gratis and sampling toward products and channels with repeatable consumer response. What changes the answer: The answer changes when incremental investment supports repeat purchase and profitable replenishment rather than temporary sell-in. Test Build Versus Buy Compare internal development with acquisitions where a category, consumer group, price tier or geography remains underrepresented. What changes the answer: The answer changes when the cost and time to build exceed the strategic fit available through a credible target.
- 12SECTION 04
04
Divider introducing the precedent transactions section.
This section reviews the deal record across brands, professional beauty and broader portfolios. So what: disclosed deal terms show how buyers have valued different business models in practice.
Everything on this page
SECTION 04 04 PRECEDENT TRANSACTIONS Disclosed Deal Values Sit Alongside a Wide EBITDA Range The transaction record spans brands, professional beauty and broader portfolios. 04 of 06 Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12
- 1304 · DEAL CASE STUDIES
Precedent Transactions Span Brands, Portfolios and Professional Beauty
This slide presents 3 of 15 disclosed-terms transactions as detailed case studies.
We walk through 3 of the 15 transactions with disclosed terms as case studies, with multiples on LTM financials at announcement where disclosed. The complete list sits in the appendix, and these deal multiples are not directly comparable to the CY2027E public basis. So what: the case studies show why buyers paid what they paid, informing how a target's own model might be tested by a future counterparty.
Everything on this page
04 · DEAL CASE STUDIES Precedent Transactions Span Brands, Portfolios and Professional Beauty 3 of 15 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 25 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 18 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Feb-2019 $16.1B JAB Holding Company S.à r.l. JAB Holding Company S.à r.l. pursued Coty Inc. at substantial portfolio scale. EV / LTM revenue 1.8x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests interest in a broad beauty portfolio with established brand and channel reach. Its scale distinguishes it from single-brand precedents. HOW THE TARGET WAS VALUED The disclosed value was $16.1B at 1.8x EV / Revenue. This provides a revenue cross-check rather than a direct benchmark under the lead EV / EBITDA lens. Jul-2015 $12.5B Coty Inc. acquires Galleria Co. EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED Value shown as recorded in the filing; deal value unit unresolved. HOW THE TARGET WAS VALUED The filing records $12.5B of enterprise value. Jun-2020 $4.3B Kohlberg Kravis Roberts & Co. L.P. Kohlberg Kravis Roberts & Co. L.P. acquired Professional Beauty Business at platform scale. EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests sponsor interest in a professional beauty platform with established channel reach. The fit rests on category position and scale rather than a single consumer brand. HOW THE TARGET WAS VALUED The disclosed value was $4.3B. The transaction provides a scale benchmark, while no multiple is used in the valuation comparison.
- 14SECTION 05
05
Divider introducing the strategic implications section.
This section turns the valuation and deal evidence into questions owners can act on over the next twelve months. So what: durable growth needs proof at the consumer, product and channel level, not just headline momentum.
Everything on this page
SECTION 05 05 STRATEGIC IMPLICATIONS Durable Growth Requires Proof at the Consumer, Product and Channel Level Owners can strengthen their standing through revenue quality, franchise depth and disciplined investment. 05 of 06 Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14
- 1505 · STRATEGIC IMPLICATIONS
Owners Can Strengthen Value Through Better Revenue Quality and Franchise Depth
This slide sets out the operating questions the data raises for owners over the next twelve months.
We frame the questions this data puts on the table: how to build growth that survives scrutiny, protect margin without starving newness, and allocate capital by business model. These are directional views drawn from the analysis shown earlier, offered as observations rather than recommendations. So what: owners who address revenue quality and franchise depth now are better positioned when the market re-rates the sector.
Everything on this page
05 · STRATEGIC IMPLICATIONS Owners Can Strengthen Value Through Better Revenue Quality and Franchise Depth NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Build Growth That Survives Scrutiny Prioritise consumer offtake, repeat purchase and productive distribution. Growth supported by these measures is easier to distinguish from shipment timing or promotion. FOR MANAGEMENT TEAMS Protect Margin Without Starving Newness Align innovation cadence, trade spend and A and P investment with the franchises and channels showing durable consumer response. FOR BOARDS Allocate Capital by Business Model Assess brands, licences, direct-to-consumer channels and adjacent models on their own economics. The peer set shows that one sector label can contain very different valuation positions.
- 16SECTION 06
06
Divider introducing the appendix covering the comparable universe, methodology and sources.
This section carries the comparables detail behind every figure in the body, the valuation basis and where each underlying disclosure lives. So what: any figure in this deck can be traced back to its source.
Everything on this page
SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16
- 1706 · PUBLIC COMPARABLES (1 OF 1)
Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier
This slide lists all public comparables on EV/EBITDA (CY2027E), grouped by valuation tier.
We show all 7 rated companies and the 2 not rated, grouped by valuation tier against the 15.2x sector median, with tickers linking to the underlying source. So what: this is the full rated universe behind every multiple quoted earlier in the deck.
Everything on this page
06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (15.2x); amber marks below · 7 rated companies; 2 not rated (no eligible EV/EBITDA) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 7 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥18.4x · median 23.2x · 2 companies LandBridge Company LLC LB Adjacent: land and mineral royalties $7.2B 25.4x n/a n/a n/a Oddity Tech Ltd. ODD Mass personal care brands $1.3B 20.9x 15% 8% 23 CORE — 10.6x–18.4x · median 15.2x · 3 companies e.l.f. Beauty, Inc. ELF Mass personal care brands $6.6B 15.8x 11% 20% 31 Inter Parfums, Inc. IPAR Mass personal care brands $4.0B 15.2x 7% 16% 24 The Estée Lauder Companies Inc. EL Mass personal care brands $40.8B 13.2x 4% 19% 23 DISCOUNT — <10.6x · median 5.8x · 2 companies Coty Inc. COTY Mass personal care brands $5.9B 8.0x -5% 14% 9 Betterware de Mexico, S.A.P.I. de C.V. BWMX Beauty specialty retail and direct-to-consumer $860M 3.6x 17% 20% 37
- 1806 · PRECEDENT TRANSACTIONS (1 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This slide lists precedent transactions with disclosed terms, newest first.
We list transactions with disclosed terms, newest first, with multiples on LTM financials at announcement where disclosed and deal values linked to the underlying filing. So what: this is the primary evidence base behind the deal case studies shown earlier.
Everything on this page
06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 15 transactions with disclosed terms in this tier (33 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 25 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 18 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jun-2026 Bridgepoint → Obagi Medical $460M n/a n/a Bridgepoint acquired Obagi Medical for $460M. The transaction suggests continued interest in scaled brands with a defined category position. Nov-2025 n/a → The Procter & Gamble Company n/a n/a 14.0x Nov-2025 n/a → The Procter & Gamble Company n/a n/a 15.8x Value shown as recorded in the filing; status defaulted announced. Nov-2021 Waldencast Acquisition Corp. → Obagi Global Holdings Limited and Milk Makeup LLC n/a n/a 17.2x Nov-2021 Kohlberg Kravis Roberts & Co. L.P. → Wella n/a n/a 12.3x Value shown as recorded in the filing; deal value unit unresolved. Jun-2020 Kohlberg Kravis Roberts & Co. L.P. → Professional Beauty Business $4.3B n/a n/a Kohlberg Kravis Roberts & Co. L.P. acquired Professional Beauty Business. The target adds a professional channel and portfolio angle to the transaction record. May-2019 Natura & Co Holding S.A. → Avon Products, Inc. n/a n/a 9.5x Mar-2019 Church & Dwight Co., Inc. → Flawless & Finishing Touch (IdeaVillage Products) n/a n/a 16.4x Value shown as recorded in the filing; deal value unit unresolved. Feb-2019 JAB Holding Company S.à r.l. → Coty Inc. $16.1B 1.8x n/a JAB Holding Company S.à r.l. pursued Coty Inc. The transaction sits at the scaled portfolio end of the selected precedents.
- 1906 · PRECEDENT TRANSACTIONS (2 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This slide continues the list of precedent transactions with disclosed terms, newest first.
We continue the same list of disclosed-terms transactions, newest first, on the same LTM-at-announcement basis. So what: together, these two pages give a client the full disclosed-terms record to check any deal comparison independently.
Everything on this page
06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 15 transactions with disclosed terms in this tier (33 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 25 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 18 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Apr-2017 LVMH Moët Hennessy Louis Vuitton S.E. → Christian Dior S.E. n/a n/a 15.6x Jan-2017 Coty Inc. → Younique, LLC $600M n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Jun-2016 Revlon, Inc. → Elizabeth Arden, Inc. n/a n/a 34.3x Jul-2015 Coty Inc. → Galleria Co. $12.5B n/a n/a Value shown as recorded in the filing; deal value unit unresolved. n/a n/a → The Estée Lauder Companies Inc. n/a 3.5x n/a Value shown as recorded in the filing; status defaulted announced. n/a n/a → The Estée Lauder Companies Inc. $0M 3.5x n/a Value shown as recorded in the filing; status defaulted announced.
- 2006 · METHODOLOGY
Sources, Assumptions and Data Quality
Sources, Assumptions and Data Quality.
Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. 20
Everything on this page
06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice 20 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 9 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Cosmetics and Beauty Products and it clears the coverage gate with 7 of 9 companies (78%). EV / Revenue, P / E are carried as a cross-check. The set earns: 7 of the 7 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 3 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 403 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (402) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.
- 21
In This Set, Higher Forward Multiples Sit with Faster Growth, While Margins Vary.
Closing slide restating that higher forward multiples sit with faster growth while margins vary.
We close on the finding that carries through the whole deck: higher forward multiples sit with faster growth, while margins vary across the set. The companion tables carry the full universe and source index for any figure a client wants to trace. So what: growth quality, not category label, is what the market is pricing in this sector today.
Everything on this page
In This Set, Higher Forward Multiples Sit with Faster Growth, While Margins Vary. NeuraCap AI — Cosmetics and Beauty Products Coverage September 2026 · Prepared by NeuraCap AI · Confidential Cosmetics and Beauty Products Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21
Sources and methodology
This report covers Cosmetics and Beauty Products (Consumer Staples › Household and Personal Products › Cosmetics and Beauty Products) with market data and consensus estimates as of September 28, 2026. The company universe is the 9 listed companies whose core business is Cosmetics and Beauty Products according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Betterware de Mexico, S.A.P.I. de C.V. (BWMX), Coty Inc. (COTY), The Estée Lauder Companies Inc. (EL), e.l.f. Beauty, Inc. (ELF), Inter Parfums, Inc. (IPAR), LandBridge Company LLC (LB), Oddity Tech Ltd. (ODD), Solesence, Inc. Common Stock (SLSN), Yatsen Holding Limited (YSG). The market map groups them by business vertical — Mass personal care brands: 7 companies (EL, ELF, COTY, IPAR, ODD, YSG, SLSN); Adjacent models: 2 companies (LB, BWMX). 7 of the 9 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
Scope and company universe
This report covers Cosmetics and Beauty Products (Consumer Staples › Household and Personal Products › Cosmetics and Beauty Products) with market data and consensus estimates as of September 28, 2026. The company universe is the 9 listed companies whose core business is Cosmetics and Beauty Products according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Betterware de Mexico, S.A.P.I. de C.V. (BWMX), Coty Inc. (COTY), The Estée Lauder Companies Inc. (EL), e.l.f. Beauty, Inc. (ELF), Inter Parfums, Inc. (IPAR), LandBridge Company LLC (LB), Oddity Tech Ltd. (ODD), Solesence, Inc. Common Stock (SLSN), Yatsen Holding Limited (YSG). The market map groups them by business vertical — Mass personal care brands: 7 companies (EL, ELF, COTY, IPAR, ODD, YSG, SLSN); Adjacent models: 2 companies (LB, BWMX). 7 of the 9 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
What was excluded and why
3 records failed a validation gate and never feed a statistic in this report (3 excluded from aggregate). Each exclusion, with its reason: COTY — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · EL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · YSG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate)
Primary valuation basis and how it was chosen
Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 9 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Cosmetics and Beauty Products and it clears the coverage gate with 7 of 9 companies (78%). EV / Revenue, P / E are carried as a cross-check. The set earns: 7 of the 7 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 7 of 9 companies; EV / rEVenue: 7 of 9 companies; P/E: 6 of 9 companies.
How the multiples and statistics are computed
Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥18.4x, Core 10.6x–18.4x, Discount <10.6x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 15.2x = median(ev_ebitda CY2027E) (7 rated companies) · 23.2x = median(ev_ebitda CY2027E) within Premium tier (n=2) · 15.2x = median(ev_ebitda CY2027E) within Core tier (n=3) · 5.8x = median(ev_ebitda CY2027E) within Discount tier (n=2) · 15.8x = median(ev_ebitda CY2027E) | growth ≥ 9% (n=3) · 13.2x = median(ev_ebitda CY2027E) | growth < 9% (n=3) · 13.2x = median(ev_ebitda CY2027E) | EBITDA margin ≥ 18% (n=3) · 15.2x = median(ev_ebitda CY2027E) | EBITDA margin < 18% (n=3) · 23% = median Rule of 40 score (revenue growth + EBITDA margin) (n=6)
Precedent transactions: what is in the record and why
The precedent record holds the M&A transactions in Cosmetics and Beauty Products recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 33 transactions were recorded for this industry; 15 are shown. 18 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 11 × no evidence record; 12 × deal value unit unresolved; 2 × duplicate precedent id. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.
Sources
Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 407 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.
Interpretation and important notice
Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.
Sources linked in the report
- The Estée Lauder (EL) (sec.gov)
- e.l.f. Beauty (ELF) (sec.gov)
- Coty (COTY) (sec.gov)
- Inter Parfums (IPAR) (sec.gov)
- Solesence, Inc. (SLSN) (sec.gov)
- LandBridge Company (LB) (sec.gov)
- $16.1B (sec.gov)
- $12.5B (sec.gov)
- $4.3B (sec.gov)
- $460M (sec.gov)
- n/a (sec.gov)
- 14.0x (sec.gov)
- n/a (sec.gov)
- 17.2x (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- 15.6x (sec.gov)
- $600M (sec.gov)
- n/a (sec.gov)
- sec.gov (402) (sec.gov)
- home.treasury.gov (1) (home.treasury.gov)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Consumer Staples
- Company Report · 25 September 2026Domino's Pizza Company Valuation & Strategic Insights — September 2026
- M&A Update · 29 September 2026Food Distributors M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Food Distributors Sector Outlook — September 2026
- M&A Update · 29 September 2026Food Ingredients and Flavorings M&A update, 14–28 September 2026
Want this analysis for a company in Cosmetics and Beauty Products?
Company valuation reports run the same method against a single business — public or private.
